MCID: ANG015
MIFTS: 57

Angioedema

Categories: Rare diseases, Immune diseases, Bone diseases, Genetic diseases, Skin diseases

Aliases & Classifications for Angioedema

MalaCards integrated aliases for Angioedema:

Name: Angioedema 12 72 51 41 14 69
Quincke's Edema 12 72
Angioneurotic Oedema 12
Angioneurotic Edema 12
Giant Urticaria 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1558
ICD10 32 T78.3
MeSH 41 D000799
NCIt 46 C112175
UMLS 69 C0002994

Summaries for Angioedema

Disease Ontology : 12 A skin disease characterized by the rapid swelling of the dermis, subcutaneous tissue, mucosa and submucosal tissues.

MalaCards based summary : Angioedema, also known as quincke's edema, is related to angioedema, hereditary, type i and acquired angioedema, and has symptoms including peau d'orange and edema. An important gene associated with Angioedema is F12 (Coagulation Factor XII), and among its related pathways/superpathways are Collagen chain trimerization and Peptide hormone metabolism. The drugs Histamine and Omalizumab have been mentioned in the context of this disorder. Affiliated tissues include skin, tongue and heart.

Wikipedia : 72 Angioedema is an area of swelling of the lower layer of skin and tissue just under the skin or mucous... more...

Related Diseases for Angioedema

Diseases in the Angioedema family:

Angioedema, Hereditary, Type I Angioedema, Hereditary, Type Iii
Hereditary Angioedema Acquired Angioedema
Acquired Angioedema Type 1 Acquired Angioedema Type 2

Diseases related to Angioedema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 188)
# Related Disease Score Top Affiliating Genes
1 angioedema, hereditary, type i 34.3 F12 SERPING1
2 acquired angioedema 34.1 C1S SERPING1
3 hereditary angioedema 32.6 ACE BDKRB2 C1S F12 KLKB1 KNG1
4 c1 inhibitor deficiency 32.3 BDKRB2 C1S KLKB1 KNG1 SERPING1
5 allergic urticaria 30.1 KNG1 SERPING1
6 hydrops, lactic acidosis, and sideroblastic anemia 29.5 C1S KNG1 PTGS1 PTGS2 SERPING1
7 urticaria 29.1 C1S CPN1 F12 HNMT LTC4S PTGS1
8 eosinophilia-myalgia syndrome 28.8 HNMT IL5
9 sinusitis 28.6 IL5 LTC4S
10 angioedema, hereditary, type iii 12.5
11 angioedema induced by ace inhibitors 12.4
12 episodic angioedema with eosinophilia 12.3
13 acquired angioedema type 2 12.0
14 acquired angioedema type 1 11.8
15 vibratory urticaria 11.7
16 complement component 4, partial deficiency of 11.3
17 carboxypeptidase n deficiency 10.9
18 netherton syndrome 10.9
19 loiasis 10.9
20 angina pectoris 10.2 ACE KNG1
21 peroneal neuropathy 10.2 CPN1 MME
22 malignant essential hypertension 10.1 ACE KLKB1 KNG1
23 renal hypertension 10.1 ACE KLKB1 KNG1
24 episodic pain syndrome, familial, 1 10.1
25 aspirin resistance 10.1 PTGS1 PTGS2
26 lymphoma 10.1
27 laryngitis 10.1
28 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.1
29 congestive heart failure 10.0 ACE KNG1 MME
30 active peptic ulcer disease 10.0 PTGS1 PTGS2
31 blood group, i system 10.0
32 ovarian epithelial cancer 10.0 PTGS1 PTGS2
33 lupus erythematosus 10.0
34 allergic hypersensitivity disease 10.0
35 systemic lupus erythematosus 9.9
36 pancreatitis 9.9
37 endotheliitis 9.9
38 thyroiditis 9.9
39 dermatitis 9.8
40 acute pancreatitis 9.8
41 ischemia 9.8
42 chronic tic disorder 9.8 F12 IL5
43 macroglossia 9.8
44 aging 9.8
45 helicobacter pylori infection 9.8
46 anxiety 9.8
47 autoimmune lymphoproliferative syndrome, type v 9.8
48 arthritis 9.8
49 physical urticaria 9.8
50 adult-onset still's disease 9.8

Graphical network of the top 20 diseases related to Angioedema:



Diseases related to Angioedema

Symptoms & Phenotypes for Angioedema

UMLS symptoms related to Angioedema:


peau d'orange, edema

Drugs & Therapeutics for Angioedema

Drugs for Angioedema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 195)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4,Phase 2,Phase 3 51-45-6, 75614-87-8 774
2
Omalizumab Approved, Investigational Phase 4,Phase 3,Phase 2 242138-07-4
3
Icatibant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 130308-48-4, 138614-30-9 71364
4
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
5
Loratadine Approved, Investigational Phase 4,Phase 2 79794-75-5 3957
6
Zinc Approved, Investigational Phase 4 7440-66-6 32051 23994
7
Everolimus Approved Phase 4 159351-69-6 6442177
8
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 1 22916-47-8 4189
9
Ramipril Approved Phase 4 87333-19-5 5362129
10
Sirolimus Approved, Investigational Phase 4 53123-88-9 46835353 6436030 5284616
11
Angiotensin II Approved, Investigational Phase 4,Phase 2,Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
12
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5362032
13
Enalaprilat Approved Phase 4 76420-72-9 6917719
14
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
15
Bradykinin Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-82-2 439201
16
Lactitol Investigational Phase 4,Phase 2 585-86-4 3871
17 Kininogens Phase 4,Phase 3,Phase 2,Phase 1
18 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
20 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
21 Anti-Allergic Agents Phase 4,Phase 3,Phase 2
22
Histamine Phosphate Phase 4,Phase 2,Phase 3 51-74-1 65513
23 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
24 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2
25 Respiratory System Agents Phase 4,Phase 3,Phase 2
26 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
27 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
28
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
29 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
30 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
31 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
33 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Bradykinin B2 Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1
35 Bradykinin Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1
36 Complement Inactivating Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Complement System Proteins Phase 4,Phase 3,Phase 2,Phase 1
38 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Complement C1 Inactivator Proteins Phase 4,Phase 3,Phase 2,Phase 1
41 Complement C1 Inhibitor Protein Phase 4,Phase 3,Phase 2,Phase 1
42 Complement C1s Phase 4,Phase 3,Phase 2,Phase 1
43 Antipruritics Phase 4,Phase 3,Phase 2
44 Cholinergic Agents Phase 4
45 Cholinergic Antagonists Phase 4
46 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Histamine Antagonists Phase 4,Phase 3,Phase 2
48 Histamine H1 Antagonists Phase 4,Phase 3,Phase 2
49 Histamine H1 Antagonists, Non-Sedating Phase 4,Phase 2
50 Hypoglycemic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 130)

# Name Status NCT ID Phase Drugs
1 A Call Center During HAE Attacks (SOS HAE) Completed NCT01679912 Phase 4
2 Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE Completed NCT01457430 Phase 4 Icatibant
3 A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE Completed NCT00914966 Phase 4
4 Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert Completed NCT01467947 Phase 4
5 Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria Completed NCT01444196 Phase 4 Desloratadine
6 Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment Completed NCT02550106 Phase 4 OMALIZUMAB
7 Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety Completed NCT00359801 Phase 4 Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care;Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care
8 Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus Completed NCT00502242 Phase 4 ramipril;ramipril
9 Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy Recruiting NCT02966314 Phase 4 Omalizumab;Placebos
10 Comparison of Saocubitril/valsartaN Versus Enalapril on Effect on ntpRo-bnp in Patients Stabilized From an Acute Heart Failure Episode. Recruiting NCT02554890 Phase 4 sacubitril/valsartan (LCZ696);Enalapril;sacubitril/valsartan (LCZ696) matching placebo;enalapril matching placebo
11 Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema Terminated NCT01574248 Phase 4 icatibant
12 C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation Withdrawn NCT01151735 Phase 4 C-1-esterase;C-1-esterase;placebo
13 Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE Completed NCT02586805 Phase 3 DX-2930 - 300mg/2wk;DX-2930 - 300mg/4wk;DX-2930 - 150mg/4wk;Placebo
14 A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema Completed NCT01912456 Phase 3
15 C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema Completed NCT00125151 Phase 3 C1 inhibitor concentrate (C1-esteraseremmer-N)
16 C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema Completed NCT00125541 Phase 2, Phase 3 C1 inhibitor concentrate (C1-esteraseremmer-N)
17 Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy Completed NCT01723072 Phase 3 Placebo
18 Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema Completed NCT02052141 Phase 3
19 Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema Completed NCT01919801 Phase 3 Icatibant;Placebo
20 Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks Completed NCT00438815 Phase 3
21 Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema Completed NCT02584959 Phase 3 C1 esterase inhibitor [human] liquid;Placebo
22 Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema Completed NCT00097695 Phase 3 Icatibant;Placebo
23 A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3) Completed NCT00912093 Phase 3 Icatibant;Placebo
24 A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema Completed NCT02316353 Phase 3
25 Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks Completed NCT00462709 Phase 3
26 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks Completed NCT02303626 Phase 2, Phase 3 BCX4161;Placebo
27 Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE) Completed NCT00456508 Phase 3 ecallantide
28 Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE) Completed NCT00457015 Phase 3 ecallantide;Phosphate Buffer Saline (PBS), pH 7.0
29 Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Completed NCT00225147 Phase 2, Phase 3 Recombinant Human C1 Inhibitor;placebo
30 Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE) Completed NCT02865720 Phase 3 CINRYZE 500 U;CINRYZE 1000 U
31 Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE) Completed NCT00500656 Phase 3 Icatibant;Tranexamic Acid;Oral Placebo;S.C. Placebo
32 C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks Completed NCT01005888 Phase 3 Placebo (saline)
33 Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Completed NCT00262301 Phase 3 recombinant human C1 inhibitor;Placebo
34 Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Completed NCT00262288 Phase 2, Phase 3 i.v. recombinant human C1 inhibitor
35 C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study) Completed NCT00292981 Phase 3 C1 Esterase Inhibitor
36 Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks Completed NCT01188564 Phase 3 rhC1INH;Placebo (Saline)
37 Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE) Completed NCT00262080 Phase 3 ecallantide;Phosphate Buffer Saline (PBS),
38 Berinert P Study of Subcutaneous Versus Intravenous Administration Completed NCT00748202 Phase 3 C1-Esterase Inhibitor
39 EASSI - Evaluation of the Safety of Self-Administration With Icatibant Completed NCT00997204 Phase 3 Icatibant
40 Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks Completed NCT00168103 Phase 2, Phase 3
41 C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks Completed NCT00289211 Phase 3 Placebo (saline)
42 AVE7688 in Patients With Mild to Moderate Blood Pressure Completed NCT00284128 Phase 2, Phase 3 AVE7688;Losartan-potassium
43 OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients Completed NCT02161562 Phase 3 omalizumab;omalizumab
44 Bilastine Updosing in Chronic Spontaneous Urticaria Completed NCT02213367 Phase 3 Bilastine;Bilastine;Bilastin
45 Glucocorticoids With Antihistamines Versus Antihistamines in Acute Urticaria in Emergency Completed NCT02565680 Phase 2, Phase 3 placebo;prednisone
46 A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1) Completed NCT01292473 Phase 3 Placebo;Omalizumab
47 A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment Completed NCT01287117 Phase 3 Omalizumab;Placebo
48 A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists Completed NCT01264939 Phase 3 Omalizumab;Placebo;H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist;Diphenhydramine
49 Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema Recruiting NCT01843530 Phase 3 Berinert;Clemastin;Cortisone acetate;NaCl
50 Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection Recruiting NCT02365493 Phase 3 Beta-Lactam

Search NIH Clinical Center for Angioedema

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: angioedema

Genetic Tests for Angioedema

Anatomical Context for Angioedema

MalaCards organs/tissues related to Angioedema:

38
Skin, Tongue, Heart, Brain, Liver, Endothelial, Thyroid

Publications for Angioedema

Articles related to Angioedema:

(show top 50) (show all 1342)
# Title Authors Year
1
Health-Related Quality-of-Life with Subcutaneous C1-inhibitor for Prevention of Attacks of Hereditary Angioedema. ( 29391286 )
2018
2
Hereditary Angioedema with Normal C1 Inhibitor: Four Types and Counting. ( 29410040 )
2018
3
The international WAO/EAACI guideline for the management of hereditary angioedema - the 2017 revision and update. ( 29318628 )
2018
4
Orolingual and abdominal angioedema post thrombolysis and thrombectomy. ( 29335305 )
2018
5
Use of pdC1-INH concentrate for long-term prophylaxis during pregnancy in hereditary angioedema with normal C1-INH. ( 29439936 )
2018
6
Plasma Prekallikrein: Its Role in Hereditary Angioedema and Health and Disease. ( 29423395 )
2018
7
Presymptomatic genetic diagnosis of two siblings with hereditary angioedema, presenting with unusual normal levels of serum C4. ( 29058329 )
2018
8
Evaluating satisfaction of patients with hereditary angioedema with their past and present treatments: Implications for future therapies. ( 29279063 )
2018
9
New Treatments for Hereditary Angioedema. ( 29357215 )
2018
10
Investigational drugs in phase I and phase II clinical trials for hereditary angioedema. ( 29226721 )
2018
11
Exposure-Response Model of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema. ( 29316335 )
2018
12
Hereditary and Acquired Angioedema: Heterogeneity of Pathogenesis and Clinical Phenotypes. ( 29393169 )
2018
13
Novel Therapies for Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema: A Systematic Review of Current Evidence. ( 28939396 )
2017
14
Outcomes of long term treatments of type I hereditary angioedema in a Turkish family. ( 29166502 )
2017
15
Granulomatous cheilitis mimicking angioedema. ( 28632806 )
2017
16
Emerging Therapies in Hereditary Angioedema. ( 28687111 )
2017
17
Persistent oromandibular dystonia and angioedema secondary to haloperidol. ( 28978587 )
2017
18
Pediatric Angioedema. ( 28791569 )
2017
19
Recombinant human C1 esterase inhibitor for acute hereditary angioedema attacks with upper airway involvement. ( 28903805 )
2017
20
Disease Severity, Activity, Impact, and Control and How to Assess Them in Patients with Hereditary Angioedema. ( 29255709 )
2017
21
Comparison of the Frequency of Angioedema Attack, before and during Pregnancy, in a Patient with Type I Hereditary Angioedema. ( 29093422 )
2017
22
Acute dystonic reaction leading to lingual hematoma mimicking angioedema. ( 29326495 )
2017
23
Acquired Arnold-Chiary malformation in a 16-year-old patient with hereditary angioedema. ( 28881398 )
2017
24
Angioedema, Stomatitis, and Urticaria Caused by Contact Allergy to Invisalign. ( 28885312 )
2017
25
A Case of Type 2 Hereditary Angioedema With SERPING1 Mutation. ( 27826968 )
2017
26
Thrombolysis of a stroke patient with history of rtPA-associated angioedema. ( 29431157 )
2017
27
A case of non-episodic angioedema with eosinophilia induced by influenza vaccine. ( 28943505 )
2017
28
Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema: Findings from an international patient registry. ( 27865714 )
2017
29
Recurrent angioedema associated with pharmacological inhibition of dipeptidyl peptidase IV. ( 28073873 )
2017
30
Treatment of hereditary angioedema due to C1 inhibitor deficiency in Argentina. ( 28825570 )
2017
31
Angioedema. ( 28818177 )
2017
32
Genetic Determinants of C1 Inhibitor Deficiency Angioedema Age of Onset. ( 29130992 )
2017
33
Mimicker of hereditary angioedema: Idiopathic systemic capillary leak syndrome successfully treated with intravenous immunoglobulin. ( 28377172 )
2017
34
Glucocorticoid receptor gene polymorphisms in hereditary angioedema with C1-inhibitor deficiency. ( 28069032 )
2017
35
Current and future therapies for the treatment of histamine-induced angioedema. ( 28081650 )
2017
36
The Search for Biomarkers in Hereditary Angioedema. ( 29214154 )
2017
37
Pharmacoeconomics of Orphan Disease Treatment with a Focus on Hereditary Angioedema. ( 28687113 )
2017
38
Mutational spectrum of the SERPING1 gene in Swiss patients with hereditary angioedema. ( 28194776 )
2017
39
Recognizing a Rare Phenomenon of Angiotensin-Converting Enzyme Inhibitors: Visceral Angioedema Presenting with Chronic Diarrhea-A Case Report. ( 29236651 )
2017
40
Hereditary angioedema in 2 sisters due to paternal gonadal mosaicism. ( 28888847 )
2017
41
A Case of Miller Fisher Syndrome, Thromboembolic Disease, and Angioedema: Association or Coincidence? ( 28090073 )
2017
42
Hereditary Angioedema: An Overlooked Cause of Recurrent Abdominal Pain and Free Peritoneal Fluid. ( 28780207 )
2017
43
Diagnosis, Course, and Management of Angioedema in Patients With Acquired C1-Inhibitor Deficiency. ( 28284781 )
2017
44
Clinical characteristics in cholinergic urticaria with palpebral angioedema: Report of 15 cases. ( 27876252 )
2017
45
Hypovolemic Shock Caused by Angiotensin-Converting Enzyme Inhibitor-Induced Visceral Angioedema: A Case Series and A Simple Method to Diagnose this Complication in the Emergency Department. ( 29269078 )
2017
46
Idiopathic non-histaminergic acquired angioedema: a case series and discussion of published clinical trials. ( 28861213 )
2017
47
Prophylactic Therapy for Hereditary Angioedema. ( 28687109 )
2017
48
Cleaved kininogen as a biomarker for bradykinin release in hereditary angioedema. ( 28782632 )
2017
49
Acquired Angioedema. ( 28377018 )
2017
50
Pediatric hereditary angioedema: an update. ( 28781749 )
2017

Variations for Angioedema

ClinVar genetic disease variations for Angioedema:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 F12 NM_000505.3(F12): c.983C> G (p.Thr328Arg) single nucleotide variant Pathogenic rs118204456 GRCh37 Chromosome 5, 176831232: 176831232
2 SYTL2 NM_032943.4(SYTL2): c.890delG (p.Ser297Thrfs) deletion Pathogenic rs1057519445 GRCh38 Chromosome 11, 85734436: 85734436

Expression for Angioedema

Search GEO for disease gene expression data for Angioedema.

Pathways for Angioedema

Pathways related to Angioedema according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.46 DPP4 F12 KLKB1 KNG1 MME XPNPEP2
2
Show member pathways
11.97 ACE CPN1 DPP4 MME
3
Show member pathways
11.82 F12 KLKB1 KNG1 SERPING1
4
Show member pathways
11.7 LTC4S PTGS1 PTGS2
5 11.24 BDKRB2 C1S F12 KLKB1 KNG1 SERPING1
6 11.23 F12 KLKB1 SERPING1
7
Show member pathways
11.16 ACE BDKRB2 KNG1 MME
8 10.98 PTGS1 PTGS2
9
Show member pathways
10.96 PTGS1 PTGS2
10 10.87 ACE MME
11 10.86 PTGS1 PTGS2
12 10.76 PTGS1 PTGS2
13 10.71 LTC4S PTGS1 PTGS2
14 10.61 PTGS1 PTGS2

GO Terms for Angioedema

Cellular components related to Angioedema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 ACE CPN1 F12 IL5 KLKB1 KNG1
2 extracellular region GO:0005576 9.65 ACE C1S CPN1 DPP4 F12 IL5
3 extracellular exosome GO:0070062 9.36 ACE C1S DPP4 F12 HNMT KLKB1

Biological processes related to Angioedema according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.76 F12 KLKB1 KNG1 SERPING1
2 regulation of complement activation GO:0030449 9.75 C1S CPN1 SERPING1
3 inflammatory response GO:0006954 9.73 BDKRB2 IL5 KLKB1 KNG1 PTGS1 PTGS2
4 cellular oxidant detoxification GO:0098869 9.67 LTC4S PTGS1 PTGS2
5 regulation of blood pressure GO:0008217 9.65 ACE PTGS1 PTGS2
6 arachidonic acid secretion GO:0050482 9.61 ACE BDKRB2
7 regulation of vasoconstriction GO:0019229 9.61 ACE BDKRB2
8 regulation of blood coagulation GO:0030193 9.6 F12 SERPING1
9 vasodilation GO:0042311 9.59 BDKRB2 KNG1
10 prostaglandin metabolic process GO:0006693 9.58 PTGS1 PTGS2
11 lipoxygenase pathway GO:0019372 9.57 LTC4S PTGS2
12 prostaglandin biosynthetic process GO:0001516 9.56 PTGS1 PTGS2
13 proteolysis GO:0006508 9.56 ACE C1S CPN1 DPP4 F12 KLKB1
14 amyloid-beta metabolic process GO:0050435 9.55 ACE MME
15 angiotensin maturation GO:0002003 9.54 ACE MME
16 zymogen activation GO:0031638 9.52 F12 KLKB1
17 cyclooxygenase pathway GO:0019371 9.51 PTGS1 PTGS2
18 fibrinolysis GO:0042730 9.5 F12 KLKB1 SERPING1
19 hemostasis GO:0007599 9.46 F12 KLKB1 KNG1 SERPING1
20 negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress GO:1902219 9.43 BDKRB2 PTGS2
21 positive regulation of fibrinolysis GO:0051919 9.4 F12 KLKB1
22 Factor XII activation GO:0002542 9.37 F12 KLKB1
23 blood coagulation, intrinsic pathway GO:0007597 8.92 F12 KLKB1 KNG1 SERPING1

Molecular functions related to Angioedema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hydrolase activity GO:0016787 9.97 ACE C1S CPN1 DPP4 F12 KLKB1
2 serine-type endopeptidase activity GO:0004252 9.71 C1S DPP4 F12 KLKB1
3 metallopeptidase activity GO:0008237 9.62 ACE CPN1 MME XPNPEP2
4 heme binding GO:0020037 9.61 KLKB1 PTGS1 PTGS2
5 aminopeptidase activity GO:0004177 9.48 DPP4 XPNPEP2
6 peroxidase activity GO:0004601 9.46 PTGS1 PTGS2
7 serine-type peptidase activity GO:0008236 9.46 C1S DPP4 F12 KLKB1
8 exopeptidase activity GO:0008238 9.26 ACE MME
9 peptidase activity GO:0008233 9.23 ACE C1S CPN1 DPP4 F12 KLKB1
10 prostaglandin-endoperoxide synthase activity GO:0004666 8.96 PTGS1 PTGS2

Sources for Angioedema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....